Pulmonx’s Zephyr® Endobronchial Valve Demonstrates Statistically and Clinically Significant Results in a Prospective, Randomized Controlled Trial
September 09, 2014, Redwood City & Munich – The results of BeLieVeR-HIFi trial, the first double-blinded, randomized, controlled clinical trial to assess the impact of the Zephyr® Endobronchial Valve (EBV) for the treatment of emphysema, were presented today at the 2014 European Respiratory Society…
Pulmonx Announces First Comprehensive Report of Collateral Ventilation Assessed by the Chartis Endobronchial Catheter in Late Stage Emphysema
Pulmonx Products Highlighted in Multiple Presentations at ATS 2014
May 19, 2014, Redwood City, California – Pulmonx, an emerging leader in interventional pulmonology, announced today that multiple clinical abstracts examining the diagnostic and therapeutic utility of its Chartis Pulmonary…
Pulmonx Endobronchial Valve (EBV) Therapy Demonstrates Safety and Significant Long-Term Benefit in French Study
April 24, 2014, Neuchâtel, Switzerland – Pulmonx, an emerging leader in interventional pulmonology, announced today that its Zephyr® Endobronchial Valve (EBV) was featured at the 18th World Congress for Bronchology and Interventional Pulmonology (WCBIP) in Kyoto, Japan in the poster presentation…